Exercise Type That Faster Reduces Postprandial Glycemia. (GLYEXER)

It is well established that a bout of 50 min of continuous moderate intensity exercise, improves insulin sensitivity up to 48 hours after the bout. However, it is less well known, what is the exercise type more efficient to buffer the elevations in blood glucose elicited by carbohydrate ingestion. The purpose of this study is to elucidate if intervalic exercise is superior to continous on improving postprandial glycemic control.

Study Overview

• Status: Enrolling by invitation
• Conditions: Glucose, High Blood; Exercise-Induced Hyperinsulinism
• Intervention / Treatment: Behavioral: TYPE OF EXERCISE (OR REST)

Detailed Description

Carbohydrate oxidation, glucose and insulin blood concentrations, isotopically measured rate of appearance of endogenous and exogenous glucose will be measured in 4 ocassions.

Participants will undergo in a cross-over randomized fashion the following trials:

1. Exercise pedalling during 50 min at 60% of their VO2max followed by an oral glucose tolerance test (OGTT).
2. Exercise pedalling during 50 min in a hot environment (33ºC) at 60% of their VO2max followed by an oral glucose tolerance test (OGTT).
3. Exercise pedalling during 50 min using intervalic bouts averaging 60% of VO2max followed by an oral glucose tolerance test (OGTT).
4. No exercise, followed by an oral glucose tolerance test (OGTT).

• Study Type: Interventional
• Enrollment (Anticipated): 11
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Toledo, Spain, 45071
    • University of Castilla-La Mancha (Exercise Physiology Lab)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant must be capable and willing to provide consent, understand, instructions and protocols.
• Minimal fitness level to be able to complete 50 min of continous exercise at a moderate intensity.

Exclusion Criteria:

• Smokers
• Pregnancy
• Any non-controlled medical condition which could influence results or could be worsened by exercise

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AEROBIC EXERCISE; 50 min of aerobic exercise by pedaling a cycleergometer at 60% of VO2max	Behavioral: TYPE OF EXERCISE (OR REST); continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
Placebo Comparator: PLACEBO REST; No exercise, resting during 50 min.	Behavioral: TYPE OF EXERCISE (OR REST); continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood glucose concentration	Incremental area under the curve during the 120 min of the oral glucose tolerance test	16 weeks
Blood insulin concentration	Incremental area under the curve during the 120 min of the oral glucose tolerance test	16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Carbohydrate oxidation	Measured using indirect calorimetry	16 weeks
Turnover rate of endogenous and exogenous glucose	Measured using isotopic tracers.	16 weeks

Collaborators and Investigators

• Sponsor: University of Castilla-La Mancha

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2021
• Primary Completion (Anticipated): August 30, 2023
• Study Completion (Anticipated): September 10, 2024

Study Registration Dates

• First Submitted: April 11, 2021
• First Submitted That Met QC Criteria: April 14, 2021
• First Posted (Actual): April 15, 2021

Study Record Updates

• Last Update Posted (Actual): November 4, 2022
• Last Update Submitted That Met QC Criteria: November 3, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Hyperinsulinism
• Other Study ID Numbers: PID2020-116159RB-I00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Data will be shared upon reasonable request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No